Clinical & Experimental Cardiology
Open Access

Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy

Publications

• Short Communication   
  Where do we Stand in the Treatment of HCM in Children? The Role of Disopyramide and New Medications on the Horizon
  Author(s): Karin Del Vecchio*, Alice Pozza and Giovanni Di Salvo
  
  Pediatric Hypertrophic Cardiomyopathy (HCM) has a wide range of clinical manifestations. Left Ventricular Outflow Tract Obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50%-60% of symptomatic children developing a gradient under exertion. Treatment options are limited and there is a relative lack of data on the pediatric population. Disopyramide is a sodium channel blocker with negative inotropic properties. This therapy effectively reduces LVOTO in adults with HCM and delays surgical interventions, but it is not licensed for use in children. This study aimed to review and analyze the influence of disopyramide over the pathophysiological, clinical, electrocardiographic and echocardiographic characteristics of patients with HCM in infancy, childhood, adolescence and adult age. While disopyramide remains a basis in the management of pediatri.. View More»
  DOI: 10.35248/2155-9880.24.15.919

  Abstract HTML PDF